Khalid Naveed
https://orcid.org/0000-0001-8305-6234
Aqeel Javeed
https://orcid.org/0000-0003-4682-2424
Muhammad Ashraf
https://orcid.org/0000-0002-6175-6253
Amjad Riaz
https://orcid.org/0000-0002-0963-7118
Aamir Ghafoor
https://orcid.org/0000-0003-0070-0229
Adeel Sattar
https://orcid.org/0000-0003-1124-4046

Effect of nabumetone on humoral immune responses in mice

[*Efeito da nabumetona nas respostas imunes humorais em camundongos*]

Khalid *Naveed*[1], Aqeel *Javeed*[1*], Muhammad *Ashraf*[1], Amjad *Riaz*[2],
Aamir *Ghafoor*[3], Adeel *Sattar*[1]

[1]Department of Pharmacology and Toxicology, University of Veterinary and Animal Sciences, Lahore-Pakistan
[2]Department of Theriogenology, University of Veterinary and Animal Sciences, Lahore-Pakistan
[3]University Diagnostic Lab, University of Veterinary and Animal Sciences, Lahore- Pakistan

ABSTRACT

Nabumetone is used to reduce the pain and inflammation in rheumatoid arthritis. In the current study, immunomodulatory effect of Nabumetone is investigated in mice. The control group was administered normal saline orally as placebo. Nabumetone was administered orally via gavage in two treatment groups at 14mg/kg.b.w. doses and 28mg/kgb.w., respectively. Haemagglutination (HA) assay, Jerne hemolytic plaque and mice lethality assays were applied. In HA assay, the titer was significantly decreased in Nabumetone treatment groups (P< 0.001). In Jerne hemolytic plaque formation assay, there was a significant reduction (P< 0.001) in number of plaques in Nabumetone treated groups when compared with control. In mice lethality assay, there was a significant difference in mortality ratio of mice in control and Nabumetone treated groups (P< 0.001). Therefore, it is concluded that Nabumetone suppresses the humoral immune response in mice.

Keywords: nabumetone, humoral immunity, mice

[RESUMO]

A nabumetona é usada na redução da dor e inflamação da artrite reumática. No presente estudo, o efeito imunomodulador é investigado em camundongos. O grupo de controle recebeu solução salina via oral como placebo. Nabumetona foi administrada oralmente via gavagem em dois grupos de tratamentos com doses de 14mg/kg.b.w. e 28mg/kgb.w., respectivamente. Foram realizados ensaios de hemaglutinação (HA), placa hemolítica de Jerne e letalidade dos camundongos. No ensaio HA, o grau foi significativamente menor nos grupos de tratamento com nabumetoma (P< 0.001). No ensaio de formação de placa hemolítica de Jerne houve redução significativa (P< 0.001) no número de placas em grupos tratados com nabumetoma comparado ao controle. No ensaio de letalidade dos camundongos houve diferença significativa no grau de mortalidade de camundongos no grupo de controle e grupos tratados com nabumetoma (P< 0.001). Portanto, conclui-se que a Nabumetoma suprime a resposta imune humoral em camundongos.

Palavras-chave: nabumetoma, imunidade humoral, camundongos

INTRODUCTION

Nabumetone is a non-acid pro-drug approved by the Food and Drug Administration authority in 1991. It is a non-steroidal anti-inflammatory drug used in conditions such as rheumatoid arthritis, osteoarthritis, and any other disease associated with pain. Nabumetone is a pro-drug.

Therefore, it is essentially taken through oral route. Nabumetone is derived from 1-naphthyl acetic acid and inhibits the cyclooxygenase enzymes (Hassan *et al.,* 2004). It belongs to the 2.6-substituted naphthyl alkaline class of non-steroidal anti-inflammatory drugs, and 6-methoxy 2-naphthyl acetic acid is its active metabolite which is mainly responsible for its pharmacological action as this active metabolite

reaches the joint fluid (Klebanoff *et al.,* 2005; Muneer *et al.,* 2005). It has been found that Nabumetone has very few undesired health effects. Nabumetone is also used for the control of blood pressure in hypertensive patients on ACE inhibitors (Muneer *et al.,* 2005). For every 24 hours, one-gram dose is enough to produce the desired effect, and its effect is roughly equivalent to other group members like naproxen, indomethacin, decolophenic, sulindac, aspirin and ibuprofen. However, Nabumetone exhibits little negative effects that is why it is tolerated (Gonzalo-Garijo *et al.,* 2007).

Cyclo-oxygenases are not directly involved in different functions, but they result in the production of prostanoids (prostaglandins, prostacyclin and thromboxane), which are responsible for different immunomodulatory effects. Immunity, which defends the host from infections, may be acquired or innate. COX-2 expression is increased during inflammation and may play an important role in immune regulation. Cyclooxygenase-1 shows some physiological functions (Bernard *et al.,* 2010).

The role of the humoral immune system is to produce antibodies in order to defend the body against variety of pathogens (Kerola *et al.,* 2009). Humoral or antibody immune responses protect against bacterial attack. After stimulation of B cells, IgA and IgG are produced to destroy pathogens (Kruetzmann *et al.,* 2003). B cells are produced from plasma cells (Fulzele *et al.,* 2003). Plasma cells can release large amounts of a single type of antibody. Varieties of plasma cells have been tested to explore the mechanism of formation of B cells. The decrease of B and T lymphocytes occurs due to the lack of immune functions (Shapiro-Shelef and Calame, 2005).

Nabumetone is immunosuppressant (Koenig *et al.,* 2016). This drug may inhibit cell mediated immunity and antibody titer and lower the defense power of the body. Due to its immunosuppressant property, this may be considered as a potential drug for organ transplantation and autoimmune diseases due to its antipyretic, anti-inflammatory and analgesic effects. Therefore, the humoral immunomodulatory effect of Nabumetone was studied in the present study. The purpose of the present work was to evaluate the immunomodulatory of Nabumetone in albino mice which might help to prevent the rejection of transplanted organs and autoimmune disorders.

MATERIALS AND METHODS

Albino mice were provided by the University of Veterinary and Animal Sciences in Lahore, Pakistan. In a standard environment, these experimental animals were kept in a separate house for research purposes. In the present research, mice at five to seven weeks of age were used. All hygienic standards were observed throughout experiment. The mice were provided with hygienic, clean water ad libitum and with pelleted feed. All international standards for the maintenance and care of laboratory animals were followed in all experiments.

Antigen: Sheep red blood cells were obtained from the department of microbiology of the UVAS, Lahore. A *Pasteurella multocida* culture was obtained from the diagnostic laboratory of the UVAS, Lahore.

Chemicals: Nabumetone {($C_{15}H_{16}O_2$) 4-(6-methoxynaphthalene-2-yl) butan-2-one-Arthaxan} with molecular weight of 228.291 g/mol; CAS no. 42924-53-8 and 98% purity was the product of Alfa Aesar, A Johnson Mathey Company, whereas cyclosporine was obtained from Santa Cruz Biotechnology, USA.

Experimental design: The mice were divided into three groups i.e two treatment groups and one control group. One treatment group was given Nabumetone at a 14mg/kgb.w dose through oral route. The other treatment group was given 28mg/kgb.w. Nabumetone. Normal saline was given as placebo to the control group using a gavage needle. In the treatment groups, Nabumetone was given through the oral route by a gavage needle.

Haemagglutination assay: Mice of the same weight and age were purchased and divided into 3 equal groups. Group 1 was kept as control and not given any drugs except normal saline, whereas group 2 and group 3 were given Nabumetone through the oral route at 14mg/kg b.w. and 28mg/kg b.w., respectively. Mice in all groups were injected with sheep red blood cells intraperitoneally at 0.5×10^8 on the 14th and 21st days of trial. Blood samples were collected from all three groups, and serum was separated. Antibody titers against sheep red blood cells

916

Arq. Bras. Med. Vet. Zootec., v.72, n.3, p.915-920, 2020

were determined through a hemagglutination inhibition test. The samples were centrifuged at 1000RPM at 4ºC for 5min. The samples were frozen and tested for hemagglutination according to a method described previously (Hassan *et al.,* 2004). The results for treatment groups were compared with those for the control group.

This assay was performed to determine the antibodies titers against sheep red blood cells (SRBCs) according to the method described previously (Jerne *et al.*, 1974). Group 1 was kept as control and given normal saline orally, while group 2 and group 3 were administered Nabumetone at dose 14mg/kg. b.w. and 28mg/kg b.w., respectively, daily for 7 days. Moreover, on the 2nd day all groups were exposed to 5% of washed SRBCs at dose 0.2uL. On the 6th day, mice were sacrificed by injecting ketamine hydrochloride (10mg/kg.b.w.) intraperitoneally. Spleen was collected, crushed and strained to form a homogenous suspension of single cells in 10 milliliters chilled RPMI-1640 medium to inhibit premature release of antibodies from the cells. The number of splenic cells defined was 1×10^6/ml of RPMI. This triturate was sieved and 500µl of filtrate was mixed with equal volume of 2% SRBCs and 0.7% warm agarose (Sigma Co, USA) in 200µl RPMI. This mixture was dispensed on glass slides to form a uniform layer and incubated at 37ºC for two hrs. After incubation, 10% guinea pig complement in sterilized normal saline was added and incubated overnight at 37ºC for lysis of SRBCs. The plaques were enumerated and recorded as the number of plaque forming cells per million cells as described in an earlier study (Klebanoff *et al.,* 2005).

Brain heart infusion was used as a growth medium for *Pasteurella multocida* stored for 24 hsr at 37ºC. The bacteria were suspended in 0.5% formalin solution. For the preparation of hemorrhagic septicemia vaccine, we used lanoline, bacterial suspension and mineral oil (5:45:50) (Muneer *et al.,* 2005). Mice were treated with Nabumetone at 14mg/kg b.w. and 28mg/kg b.w. doses for 21 consecutive days, whereas, negative control group was kept as control and injected with normal saline. To ensure the viability of the vaccine, one group was kept as vaccinated control. The animals were injected with hemorrhagic septicemia vaccine on 7th and 17th day of the experiment. Whereas the

positive control group was administered cyclosporine at a 100µg/kg b.w dose through an oral catheter. On the 21st day, all mice were challenged with Pasteurella multocida culture containing 10^7 cells per ml (0.2ml). The animals were kept under observation for 72hrs for determination of mortality in all treated groups.

The data were analyzed with the help of statistical tool one-way analysis of variance (ANOVA) and comparison test i.e LSD (least significant difference) to elaborate the statistical difference between different groups. Statistical package of social sciences (SPSS) is used for more precise description of results. The P value was at P< 0.05.

RESULTS

There was a decrease (P< 0.01) in serum anti sheep red blood cells titer in the Nabumetone (14mg/kg.b.w.) treated group. Whereas, significant decrease (P< 0.001) in hemagglutination titer was observed in the group treated with a 28mg/kg.b.w. dose when compared to the control group. So, the titer was lowest in group treated with Nabumetone @28mg/kg.b.w when compared to the group treated with a 14mg/kg.b.w. dose (Figure 1).


Figure 1. Anit SRBC antibody titer at different doses (14mg/kg, 28mg/kg) of Nabumetone.n=5, **P< 0.01, ***P< 0.001 a

There was a decrease trend in the production of plasma cells in Nabumetone treated mice. The antigen antibody reaction resulted in plaque formation. Nabumetone resulted in reduced plasma cell formation which ultimately lead to low production of antibodies. Whereas, high plaque formation was observed in the control group (Figure 2).

Figure 2. Jerne hemolytic plaque formation when treated with Nebumetone @ 14mg/kg b.w. and 28mg/kg b.w. in mice

Mortality was observed in Nabumetone and cyclosporine treated groups. In non-vaccinated groups, all mice died within 24 hr after treatment

which suggested the viability of vaccine. No mortality was observed in the vaccinated group without Nabumetone. Further, immunity was not suppressed in the vaccinated negative control Nabumetone treated groups. Whereas, 100% mortality was observed in the positive control group, while 50% mortality was observed in the Nabumetone treated group at a 14mg/kg b.w. dose in mice. However, 100% mortality was observed in the Nabumetone treated group at a 28mg/kg b.w. dose. Cyclosporine was injected in mice at a 100µg/kg b.w. dose in the positive control group. Mortality rate was higher with a high dose of Nabumetone (Table 1).

Table 1. Percentage mortality in control and Nabumetone treated groups @14mg/kg b.w. and 28mg/kg b.w.

Mortality	Nabumetone not given		Nabumetone given		
	Vaccination + N.salin	No vaccine + N.Saline	14mg/kg	28mg/kg	Cyclosporine given
	n=6	n=6	n=6	n=6	n=6
Deaths after 24h	0	6	2	5	6
Deaths after 48h	0	0	1	1	0
Deaths after 72h	0	0	0	0	0
Percent deaths	0	100%	50%	100%	100%

DISCUSSION

Active metabolite of Nabumetone i-e 6MNA inhibits prostaglandin synthesis via inhibition of COX-2 enzyme (Matsumoto *et al.,* 2011). Prostaglandins increase arterial dilatation, microvascular permeability and stimulate messengers that are involved in all aspects of innate and adoptive immune responses including inflammation (Ricciotti and FitzGerald, 2011). Immune responses may result in autoimmune disorders. Immunomodulatory drugs are required in autoimmune diseases.

In present study Nabumetone was given once daily as a single dose in mice. Its active metabolite reached all body parts in mice. Moreover, it was administered orally in mice. Plasma half-life of metabolite of Nabumetone is 24 hours. It is taken once daily as a single dose. Its active metabolite reaches all body parts after ½ hour of its administration. As it is a prodrug it must be taken orally (Nobilis *et al.,* 2013).

Humoral immunity is vital for protection of the body against bacterial infections. Lungs respond against bacterial infection as B-cells lead to the production of immunity. IgG and IgA are produced which treats the systemic or local bacterial infection. B-cells lead to formation of plasma cells which results in secretion of antibodies of same type. B-cells also lead to the production of specified microorganisms (Ettinger *et al.,* 2005). In some recent immunological studies, IgM response was studied against SRBCs (Ettinger *et al.,* 2005; Maseda *et al.,* 2014). In hemagglutination assay SRBCs were used for immunization and hemagglutination.

Hemagglutination titer is used to evaluate the humoral immunity based on antigen antibody interaction. For the ease uptake by the phagocytic cells, antibody turns antigen in a suitable form that can be easily ingested. B-cells lead to the secretion of immunoglobulins which destroy the antigen. Further, B-cells are responsible for cytokines as well as antibody

production through antibodies secreting cells production, which forms when B-cells interact with antigen and lead to diminish the effect of antigen when it interacts with antibodies (Muneer *et al.,* 2005). In this study, it has been proved that due low production of antibodies, hemagglutination titer was decreased steadily when the Nabumetone was given to mice through oral gavage. This phenomenon was dose dependent as low titer was observed at a 28mg/kg b.w. dose. HA titer showed that there was lower formation of immunoglobulin G or M in all Nabumetone treated groups when exposed to SRBCs.

Spleen plays its vital role in humoral as well as cellular immunity by the stimulation of antibodies producing cells which ultimately lead to the production of antibodies. Lymphocytes and plasma cells are mainly responsible for the production of immunity. Antigen antibody complement is formed in guinea pig. When antibody is formed, it leads to the formation of plaque, however, those cells which produce the antibodies can be seen in the center of the plaque. It is due to the IgM antibody which has ability to attach with complement (Kruetzmann *et al.,* 2003). In our study, dose dependent phenomena were observed where the significant reduction in plaque formation was observed in high dose group (28mg/kg b.w.), while the plaque formation was maximum in the control group that did not receive any drug. This showed low antibody production when the dose of Nabumetone was increased.

Vaccines have been used in order to produce the humoral immunity. Firstly, the body is immunized with vaccine than bacteria are exposed in order to determine the mortality ratio. Vaccination leads to the production of antibodies. Mice have the ability to produce antibodies by the exposure of vaccine and there are more chances of survival when they are exposed to pathogenic bacteria, but it depends upon the production of sufficient antibodies. *Pasturella Maltocida* is a pathogenic organism which mostly spread through airways (Klebanoff *et al.,* 2005). In this study, mice were first exposed with hemorrhagic septicemia vaccine then to bacteria. Consequently, there was 50% mortality in mice exposed to Nabumetone at

dose 14mg/kg b.w., while 100% mortality was observed in mice exposed to a higher dose (28mg/kg b.w.). Control group showed no mortality. So, Nabumetone worked as an immunosuppressive agent.

REFERENCES

BERNARD, M.P.; BANCOS, S.; CHAPMAN, T.J.; RYAN, E.P. *et al.* Chronic inhibition of cyclooxygenase-2 attenuates antibody responses against vaccinia infection. *Vaccine*, v.28, p.1363-1372, 2010.

ETTINGER, R.; SIMS, G.P.; FAIRHURST, A.M.; ROBBINS, R. *et al.* IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. *J. Immunol.,* v.175, p.7867-7879, 2005.

FULZELE, S.; SATTURWAR, P.; JOSHI, S.; DORLE, A. Study of the immunomodulatory activity of Haridradi ghrita in rats. *Indian J. Pharmacol.,* v.35, p.51-54, 2003.

GONZALO-GARIJO, M.; CORDOBÉS-DURAN, C.; LAMILLA-YERGA, A.; MORENO-GASTÓN, I. Severe immediate reaction to nabumetone. *J. Investig. Allergol. Clin. Immunol.,* v.17, p.274, 2007.

HASSAN, Z.M.; OSTAD, S.N.; MINAEE, B. *et al.* Evaluation of immunotoxicity induced by propoxure in C57Bl/6 mice. *Int. Immunopharmacol.,* v.4, p.1223-1230, 2004.

JERNE, N.K.; HENRY, C.; NORDIN, A.A.; FUJI, H. *et al.* Plaque forming cells: methodology and theory. *Immunol. Rev.,* v.18, p.130-191, 1974.

KEROLA, M.; VUOLTEENAHO, K.; KOSONEN, O. *et al.* Effects of nimesulide, acetylsalicylic acid, ibuprofen and nabumetone on cyclooxygenase-1-and cyclooxygenase-2-mediated prostanoid production in healthy volunteers ex vivo. *Basic Clin. Pharmacol. Toxicol.,* v.104, p.17-21, 2009.

KLEBANOFF, C.A.; GATTINONI, L.; TORABI-PARIZI, P.; KERSTANN, K. *et al.* Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. *Proc. Nat. Acad. Sci.,* v.102, p.9571-9576, 2005.

KOENIG, S.; WILDER, R.; BONVINI, E.; JOHNSON, L.S. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity. Assignee: MacroGenics, Inc., Rockville. US 8,663,634B2. . Filing: 11 July 2006. Date of patent: 4 Mar. 2014.

KRUETZMANN, S.; ROSADO, M.M.; WE, H.; GERMING, U. *et al.* Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. *J. Exp. Med*., 197, 939-945, 2003.

MASEDA, D.; BONAMI, R.H.; CROFFORD, L.J. Regulation of B lymphocytes and plasma cells by innate immune mechanisms and stromal cells in rheumatoid arthritis. Exp. Rev. Clin. Immunol., v.10, p.747-762, 2014.

MATSUMOTO, K.; NEMOTO, E.; HASEGAWA, T.; AKIMOTO, M.; SUGIBAYASHI, K. In vitro characterization of the cytochrome P450 isoforms involved in the metabolism of 6-methoxy-2-napthylacetic acid, an active metabolite of the prodrug nabumetone. *Biol. Pharm. Bull*., v.34, p.734-739, 2011.

MUNEER, R.; HUSSAIN, M.; ZAHOOR, A. Efficacy of oil based haemorrhagic septicaemia vaccine: a field trial. *Int. J. Agric. Biol*., v.7, p.571-573, 2005.

NOBILIS, M.; MIKUŠEK, J.; SZOTÁKOVÁ, B.; JIRÁSKO, R. *et al.* Analytical power of LLE–HPLC–PDA–MS/MS in drug metabolism studies: Identification of new nabumetone metabolites. J. Pharm. Biomed. Anal., v.80, p.164-172, 2013.

RICCIOTTI, E.; FITZGERALD, G.A. Prostaglandins and inflammation. *Arterioscler. Thromb. Vasc. Biol*., 31, 986-1000, 2011.

SHAPIRO-SHELEF, M.; CALAME, K. Regulation of plasma-cell development. *Nat. Rev. Immunol.*, v.5, p.230, 2005.

920

Arq. Bras. Med. Vet. Zootec., v.72, n.3, p.915-920, 2020